SCHEMBL1301007

SCHEMBL1301007

CCOc1nc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METTL3 Q86U44 1/20 0.54
TSHR P16473 1/20 0.32
HIF1A Q16665 1/20 0.32
TP53 P04637 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
PTPN1 P18031 1/20 0.31
LMNA P02545 1/20 0.31
CYP2C9 P11712 1/20 0.31
ATP6V1B2 P21281 1/20 0.31
TBXA2R P21731 1/20 0.31
EDNRA P25101 1/20 0.31
TARBP2 Q15633 1/20 0.31
THRB P10828 1/20 0.31
CNR2 P34972 1/20 0.31
EGFR P00533 1/20 0.30
PIK3CG P48736 1/20 0.30
MRGPRX4 Q96LA9 2/20 0.30
SLC16A3 O15427 1/20 0.30
SLC16A1 P53985 1/20 0.30
MCTS1 Q9ULC4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1301011 1.00 METTL3 (0.54) METTL3TSHRHIF1ATP53RXFP1
SCHEMBL1301430 0.93 METTL3 (0.54) METTL3TSHRHIF1APTPN1THRB
SCHEMBL1301433 0.93 METTL3 (0.54) METTL3TSHRHIF1APTPN1THRB
SCHEMBL1300489 0.92 METTL3 (0.53) METTL3PTPN1THRBMRGPRX4
SCHEMBL1300488 0.92 METTL3 (0.53) METTL3PTPN1THRBMRGPRX4
SCHEMBL1301597 0.92 METTL3 (0.60) METTL3TSHRHIF1ATP53RXFP1
SCHEMBL1301600 0.92 METTL3 (0.60) METTL3TSHRHIF1ATP53RXFP1
SCHEMBL12108014 0.92 METTL3 (0.52) METTL3PTPN1THRBMRGPRX4
SCHEMBL1301401 0.92 METTL3 (0.54) METTL3EGFRPIK3CGMRGPRX4
SCHEMBL1301404 0.92 METTL3 (0.54) METTL3EGFRPIK3CGMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 US claimed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 US claimed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 US disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 US disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 US disclosed
WO-2009089263-A2 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES INC. (US) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885TSHR 4868/4885HIF1A 3992/4885
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885TSHR 4868/4885HIF1A 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.